Erdafitinib is used to deal with bladder cancer that has spread to other parts of the body, or can not be removed with surgical procedure. Erdafitinib is used only if your cancer has a specific genetic marker. Erdafitinib might additionally be used for purposes not detailed in this medication overview. Both women and men making use of erdafitinib ought to use efficient birth control to stop maternity. Keep using contraception for at least 1 month after your last dosage. Your medical professional may want you to use man-made rips or other lubricating eye medicine every 2 hours while you are awake. Your cancer therapies might be postponed based on the outcomes. This use is authorized under FDA's Accelerated Approval Program. As a condition of authorization, a confirmatory trial has to show that erdafitinib provides a scientific benefit in these patients. Meaning from the NCI Drug Dictionary, Detailed scientific interpretation and other names for this medication. Targeted Cancer Therapies. Targeted Drug Erdafitinib Benefits Some Patients with Advanced Bladder Cancer. It is used in patients who have an abnormal FGFR gene in their cancer and who have attempted at least another chemotherapy medication which contains platinum that did not work well. Your physician will test for the existence of this genetics. This medicine is available only with your medical professional's prescription.
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions
** If you believe that content on the Plex is summarised improperly, please, contact us, and we will get rid of it quickly; please, send an email with a brief explanation.
https://www.drugs.com/mtm/erdafitinib.html
https://www.cancer.gov/about-cancer/treatment/drugs/erdafitinib
https://www.mayoclinic.org/drugs-supplements/erdafitinib-oral-route/description/drg-204613...
CID | MolecularFormula | MolecularWeight | CanonicalSMILES | IsomericSMILES | InChI | InChIKey | IUPACName | XLogP | ExactMass | MonoisotopicMass | TPSA | Complexity | Charge | HBondDonorCount | HBondAcceptorCount | RotatableBondCount | HeavyAtomCount | IsotopeAtomCount | AtomStereoCount | DefinedAtomStereoCount | UndefinedAtomStereoCount | BondStereoCount | DefinedBondStereoCount | UndefinedBondStereoCount | CovalentUnitCount |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
67462786 | C25H30N6O2 | 446.5 | CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC | CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC | InChI=1S/C25H30N6O2/c1-17(2)26-8-9-31(20-10-21(32-4)13-22(11-20)33-5)19-6-7-23-24(12-19)29-25(15-27-23)18-14-28-30(3)16-18/h6-7,10-17,26H,8-9H2,1-5H3 | OLAHOMJCDNXHFI-UHFFFAOYSA-N | N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-N-propan-2-ylethane-1,2-diamine | 3.2 | 446.24302422 | 446.24302422 | 77.3 | 583 | 0 | 1 | 7 | 9 | 33 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Plex Page is a Biology & Health Sciences "Online Knowledge Base," where a machine summarizes all the summaries.
Contact
General contact: [email protected]